ReviewsPlasma protein binding: From discovery to development
Section snippets
INTRODUCTION TO FREE DRUG THEORY—WHY IS PLASMA PROTEIN BINDING IMPORTANT?
High concentration of proteins in plasma and the propensity of numerous drugs to bind to them have led drug development groups to recognize the importance of plasma protein binding (PPB) in modulating the effective drug concentration at pharmacological target sites. Free drug theory (FDT) is being increasingly used to explain pharmacokinetics/pharmacodynamics (PK/PD) relationships1—FDT states that in absence of energy-dependent processes (uptake and efflux transporters, pH gradient), after
MAJOR DRUG BINDING PROTEINS IN PLASMA
Major drug-binding components in plasma are albumin (human serum albumin—HSA) (600 μM), α-acid glycoprotein (AAG) (12–30 μM), lipoproteins (γ-globulin), and erythrocytes of which drug binding to albumin and AAG has been well studied and extensively published over the past several decades. Although HSA has eight binding sites, capable of binding to endogenous compounds as well as xenobiotics with varying affinities, two major sites of HSA are primarily involved in binding ligands and show a bias
SIMPLE, THEORETICAL CONSIDERATIONS OF PPB
Plasma protein binding is believed to have a significant influence in the rate of drug diffusion between plasma and tissues (influx and efflux)9 and therefore influence clearance (Cl) and volume of distribution (Vdss) of drugs. Effect of PPB on Cl is dependent on major route of Cl of the drug and in case of hepatically cleared drugs, on the liver extraction ratio. For renally extracted drugs, Cl due to glomerular filtration and active secretion are dependent on fu as only unbound drug can be
Endocrinology/Metabolism
Plasma protein binding optimization proved to be very useful in the development of depeptidyl peptidase DPP-IV inhibitors, for the treatment of type 2 diabetes mellitus. First-generation lead compound, although very potent, needed much higher than expected plasma concentration (based on its in vitro potency) for efficacy in preclinical model.11 To understand the disconnect between potency and efficacy, when the in vitro assay was performed with mouse and human serum, compound A (Fig. 4) showed
Nonsteroidal anti-inflammatory drugs
Aspirin, naproxen, piroxicam, ibuprofen, phenylbutazone, indomethacin, flurbiprofen, ketoprofen, methyl salicylate, diflunisal (Fig. 16) are some of the well-known NSAIDS used in the clinic for the treatment of inflammation-related diseases, for example, rheumatoid arthritis and chronic pain. All NSAIDS, with the exception of aspirin, are extremely highly plasma protein bound, which impacts not only their PK properties (Vdss, Cl, and t1/2), but also the duration and magnitude of their efficacy.
Species-Dependent PPB
Although not very common, sometimes, a significant difference in PPB between species is encountered and this can sometimes have major implications in predicting/determining safety and tolerability.ce:list id="l0020">
- •
This is well exemplified in the case of anticancer drug UCN-01 (Fig. 33). UCN-01 demonstrated much unexpected PK (low Vdss, low Cl) in humans that were not predicted from preclinical data (high Vdss and high Cl). This significant difference in PK between humans and preclinical
CLINICALLY RELEVANT PPB–DDI
Clinical relevance of PPB displacement, resulting in a clinically relevant DDI has been an area of much discussion and debate.3,10,61,110., 111., 112., 113., 114., 115., 116., 117. There are several examples in literature where PPB displacement was originally proposed to cause a clinical risk, especially those with warfarin, tolbutamide, and phenytoin (all with NTI), but recent evaluation of these DDIs revealed that inhibition of metabolism of the victim drugs by the corresponding perpetrator
METHODOLOGY
Several different PPB methods have been reported to in literature, a brief summary of which is provided inTable 5.
The “gold standard” methods for PPB are equilibrium dialysis, ultrafiltration and untracentrifugation, with gel filtration method being very popular as well. Readers are encouraged to refer to some excellent reviews.38,127 Some of the major methods are briefly discussed below:
EXCEPTIONS TO FDT
Very simply, this can be described as when unbound drug in a compartment does not correlate to target receptor occupancy within that compartment, leading to a disconnect between unbound drug level and pharmacological activity. This is possible when certain key underlying assumptions of FDT are not met10,61,117:
- (a)
drug has attained steady state between plasma (plasma protein binding) and target tissue (receptor and site of action), but there are certain special cases when SS equilibrium is not
SUMMARY—DISCOVERY RESEARCH TO PRECLINICAL DEVELOPMENT STAGE
There have been extensive publications highlighting PPB optimization in drug discovery. It is widely believed that compounds that show less than 85% bindings are of little concen.95 However, “one glove fits all” theory does not work during lead optimization stage, that is, there is no “optimum/desired/cutoff” value of PPB that will ensure success of a chemical series to be successful. There are some misconceptions surrounding PPB, which are briefly discussed below:
- •
Lowering PPB and optimizing
SUMMARY—CLINICAL DEVELOPMENT STAGE
It is very useful to consider several aspects of PPB in clinical situation, as learnt from the reports sited in literature and some of the important ones are discussed below:
- •
DDI due to PPB displacement. To precipitate a DDI due to PPB displacement between two drugs, both drugs have to be (a) very highly bound and exceed concentration of the plasma protein that is (are) involved in binding of the drugs. For example, HSA concentration is approximately 600 μM, so even if two highly bound drugs
RECOMMENDATIONS (DISCOVERY RESEARCH TO PRECLINICAL DEVELOPMENT STAGE)
In early stages of drug discovery (lead identification/lead optimization stages), significant resources to perform detailed PPB evaluation is not recommended and a simple approach as outlined in Figure 52 is advised to be adopted. Final decision regarding PPB optimization strategy and assay type should be decided by drug discovery projects after thorough evaluation of project requirements, as it must be emphasized that optimum/ideal PPB values can be very different from one chemical series to
RECOMMENDATIONS (CLINICAL DEVELOPMENT STAGE)
Role of PPB on efficacy models needs to be rigorously evaluated and established throughout the preclinical and clinical development stages. Although a general scheme is outlined in Figure 53, it is up to the PK scientists to evaluate the PPB-efficacy relationships to design the best studies addressing this issue on a case-by-case basis. It is crucial to understand the differences (if any) of PPB between healthy (population in which therapeutic concentration range was initially investigated in)
REFERENCES (165)
- et al.
Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug–drug interactions from in vitro data
J Pharm Sci
(2006) Influence of race or ethnicity on pharmacokinetics of drugs
J Pharm Sci
(1997)- et al.
Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors
Bioorg Med Chem Lett
(2005) - et al.
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy
Bioorg Med Chem Lett
(2006) - et al.
Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin
Eur J Med Chem
(2006) - et al.
3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: A new class of CDK2 inhibitors
Bioorg Med Chem Lett
(2006) - et al.
Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: Design, synthesis, molecular modeling, and preliminary biological evaluation
Bioorg Med Chem
(2009) - et al.
Current perspective of TACE inhibitors: A review
Bioorg Med Chem
(2009) Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management
Clin Chim Acta
(2007)- et al.
Pharmacokinetic-pharmacodynamic modeling: Time-dependent protein binding—An alternative interpretation of clockwise and counterclockwise hysteresis
J Pharm Sci
(1992)
Clinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimise pharmacotherapy
Lancet Infect Dis
KA-672 inhibits rat brain acetylcholinesterase in vitro but not in vivo
Neurosci Lett
The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat
Epilepsy Res
On the influence of protein binding on pharmacological activity of drugs
J Pharm Sci
LC–MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501)
J Chromatogr B Analyt Technol Biomed Life Sci
Interspecies differences in in vitro etoposide plasma protein binding
Biochem Pharmacol
High-performance frontal analysis for drug-protein binding study
J Pharm Biomed Anal
The importance of plasma protein binding in drug discovery
Expert Opin Drug Discov
Targeted chronic myeloid leukemia therapy: Seeking a cure
Am J Health Syst Pharm
Human alpha-1-glycoprotein and its interactions with drugs
Drug Metab Rev
A comparison of drug protein binding and alpha 1-acid glycoprotein concentration in Chinese and Caucasians
Br J Clin Pharmacol
Differences in plasma binding of drugs between Caucasians and Chinese subjects
Clin Pharmacol Ther
Characteristics of serum protein binding of felodipine
Res Commun Mol Pathol Pharmacol
CSF as a surrogate for assessing CNS exposure: An industrial perspective
Curr Drug Metab
The importance of plasma protein binding in drug discovery
Expert Opin Drug Discov
(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: A selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
J Med Chem
Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2′-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3- (trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa
J Med Chem
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo
J Med Chem
Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: A structural basis for the reduction of albumin binding
J Med Chem
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency
J Med Chem
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: Design, synthesis, and structure-activity relationships
J Med Chem
Resistance to atracurium in rats with experimental inflammation: Role of protein binding
Acta Anaesthesiol Scand
Systemic inflammation leads to resistance to atracurium without increasing membrane expression of acetylcholine receptors
Anesthesiology
Towards a drug concentration effect relationship for QT prolongation and torsades de pointes
Curr Opin Drug Discov Devel
Tasosartan, enoltasosartan, and angiotensin II receptor blockade: The confounding role of protein binding
J Pharmacol Exp Ther
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease
Antimicrob Agents Chemother
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein
J Infect Dis
VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells
Antimicrob Agents Chemother
3,5-Dioxopyrazolidines, novel inhibitors of UDP-N- acetylenolpyruvylglucosamine reductase (MurB) with activity against gram-positive bacteria
Antimicrob Agents Chemother
Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics
Antimicrob Agents Chemother
Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents
AAPS J
Effect of plasma protein binding on in vitro–in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes
Drug Metab Dispos
Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: Correlation with drug exposure and anxiolytic efficacy
J Pharmacol Exp Ther
In vitro-in vivo correlation on delivery of drug candidates to articular cartilage
Pharm Res
Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs
Clin Pharmacokinet
Protein binding in antiretroviral therapies
AIDS Res Hum Retroviruses
Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151
J Acquir Immune Defic Syndr Hum Retrovirol
Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins
Antimicrob Agents Chemother
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
N Engl J Med
Update on the pharmacokinetic aspects of antiretroviral agents: Implications in therapeutic drug monitoring
Curr Pharm Des
Cited by (270)
Pharmacokinetic considerations for enhancing drug repurposing opportunities of anthelmintics: Niclosamide as a case study
2024, Biomedicine and PharmacotherapyIntroducing the Dynamic Well-Stirred Model for Predicting Hepatic Clearance and Extraction Ratio
2024, Journal of Pharmaceutical SciencesFree drug percentage of moxidectin declines with increasing concentrations in the serum of marsupials
2024, International Journal for Parasitology: Parasites and WildlifeEvaluation of the effect of phenylpropanoids on the binding of heparin to human serum albumin and glycosylated human serum albumin concerning anticoagulant activity: A comparison study
2024, International Journal of Biological MacromoleculesHuman Serum Albumin Immobilized On Magnetizable Beads: A Rapid Method for Compound HSA Binding Study
2024, Journal of Pharmaceutical SciencesThe solvent- and surface-dependent adsorption of the lipopeptide antibiotic daptomycin: The general necessity of adsorption tests
2023, Journal of Pharmaceutical and Biomedical Analysis